anonymous
Guest
anonymous
Guest
Why is the new marketing piece saying the majority of Rx we are getting is from stimulant switches but our new targeting plan is non-stimulant market.
Only way it will be dead is if the company stops giving it away and relies on our salesforce to actually sell.This time next year Qelbree will be dead
Supernus is the only company I worked for that pays on a list. Everyone else pays on dirt and is happy you found new writers from wherever. Can’t believe you all still have “lists.”They need to let us sell to everyone we see in our offices not 1/10 providers. Makes no sense to spend all the money on lunches for rep to sell one provider and disregard all other doctors, NP/PA. Great job Supernus! We will fall on targeting. Super easy fix.....pay us on zip codes or at a minimum everyone at addresses we are already in spending our budget.
It’s funnier that you rentSelling my Big Green Egg for rent money
No one is saying to do this?Asking offices to switch stable patients from their stimulant therapy is crazy. ?I wonder if they will want to go back to their stimulant…..
The direction management is giving us is dangerous.
No one is saying to do this?
That the Supernus way of doing things. It will never changeStill at a loss…. We hit Q1 projections to the street but no one bonused.
Still at a loss…. We hit Q1 projections to the street but no one bonused.
Do you really think it matters? Q is a dud. And I like how people think that they “sell” to an HCP. Only way to have an HCP write your drug it works better than the existing treatment or you befriend them and build trust. Culture went in the shitter a few years ago.Supernus is the only company I worked for that pays on a list. Everyone else pays on dirt and is happy you found new writers from wherever. Can’t believe you all still have “lists.”